PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPantoprazole
Protonix, Controloc control(pantoprazole)
Control, Pantoprazole, Protonix (pantoprazole) is a small molecule pharmaceutical. Pantoprazole was first approved as Protonix on 2000-02-02. It is used to treat esophagitis, gastroesophageal reflux, heartburn, helicobacter infections, and zollinger-ellison syndrome in the USA. It has been approved in Europe to treat gastroesophageal reflux.
Download report
Favorite
Top Prescription Drugs
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Pantoprazole, Protonix (discontinued: Pantoprazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pantoprazole sodium
Tradename
Company
Number
Date
Products
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDEBaxterN-217512 RX2024-02-14
3 products, RLD, RS
PANTOPRAZOLE SODIUMHikma PharmaceuticalsN-209463 RX2017-06-30
1 products, RLD, RS
PROTONIXWyethN-020987 RX2000-02-02
2 products, RLD, RS
PROTONIX IVWyethN-020988 RX2001-03-22
1 products, RLD, RS
PROTONIXWyethN-022020 RX2007-11-14
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
pantoprazoleANDA2025-09-05
pantoprazole sodiumANDA2025-10-02
pantoprazole sodium d/rANDA2022-10-05
pantoprazole sodium delayed releaseANDA2014-06-06
pantoprazole sodium delayed-releaseANDA2025-09-08
pantoprazole sodium drANDA2025-01-22
protonixNew Drug Application2025-08-19
protonix delayed-release2009-01-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
gastroesophageal refluxEFO_0003948D005764K21
helicobacter infectionsEFO_1000961D016481—
zollinger-ellison syndrome—D015043E16.4
esophagitisHP_0100633D004941K20
heartburn—D006356R12
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Pantoprazole Sodium, Protonix, Wyeth Pharms
75443702026-06-07DP
75501532024-09-30U-859
75534982024-09-30U-859
78380272024-09-30DPU-859
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BC: Proton pump inhibitors for peptic ulcer and gord
— A02BC02: Pantoprazole
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD04: Pantoprazole, amoxicillin and clarithromycin
— A02BD11: Pantoprazole, amoxicillin, clarithromycin and metronidazole
HCPCS
Code
Description
C9113
Injection, pantoprazole sodium, per vial
S0164
Injection, pantoprazole sodium, 40 mg
Clinical
Clinical Trials
1591 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———432—51564
Gastroesophageal refluxD005764EFO_0003948K216321141861
RecurrenceD012008——123631350
InfectionsD007239EFO_0000544—26991740
Lung neoplasmsD008175—C34.90132371340
Covid-19D000086382—U07.1210561839
Breast neoplasmsD001943EFO_0003869C50121971237
HemorrhageD006470MP_0001914R58127101636
UlcerD014456MPATH_579—32561026
Dentin sensitivityD003807——41321423
Show 161 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.0245110—175
NeoplasmsD009369—C8016175—1046
Non-small-cell lung carcinomaD002289——14298——43
Ovarian neoplasmsD010051EFO_0003893C5610278——41
AdenocarcinomaD000230——10276——38
Colorectal neoplasmsD015179——9195—334
Fallopian tube neoplasmsD005185——8206——30
Prostatic neoplasmsD011471—C613111—823
Endometrioid carcinomaD018269——5155——23
Squamous cell carcinomaD002294——8116—222
Show 148 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C25711——523
MelanomaD008545——612——218
SyndromeD013577——21——1517
Brain neoplasmsD001932EFO_0003833C7115——510
Head and neck neoplasmsD006258——13——59
CholangiocarcinomaD018281—C22.146———9
Skin neoplasmsD012878EFO_0004198C4426——18
Urinary bladder neoplasmsD001749—C6718———8
Hematologic neoplasmsD019337——13——37
CystadenocarcinomaD003536——43———7
Show 205 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FatigueD005221—R53.831———67
VasodilationD014664——3———36
Wound healingD014945GO_0042060—1———56
VasoconstrictionD014661——3———25
MalnutritionD044342EFO_0008572E40-E463———14
Chronic fatigue syndromeD015673EFO_0004540G93.311———34
Alzheimer diseaseD000544EFO_0000249F031———34
Drug-related side effects and adverse reactionsD064420—T88.71———23
SarcopeniaD055948EFO_1000653M62.842———13
Metabolic syndromeD024821EFO_0000195E88.8102———13
Show 88 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Refractive errorsD012030HP_0000483H52.7————2525
MyopiaD009216EFO_0003927H52.1————1414
Oxidative stressD018384EFO_1001905—————99
Gestational diabetesD016640—O24.4————88
PresbyopiaD011305—H52.4————77
Respiratory aspirationD053120EFO_1001839—————77
FistulaD005402——————77
AstigmatismD001251EFO_0004222H52.2————77
HyperopiaD006956EFO_0006310H52.0————66
Rectal fistulaD012003—K60.3————55
Show 317 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePantoprazole
INNpantoprazole
Description
Pantoprazole is a member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. It has a role as an anti-ulcer drug, an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor, a xenobiotic and an environmental contaminant. It is a member of benzimidazoles, a member of pyridines, an aromatic ether, an organofluorine compound and a sulfoxide. It is a conjugate acid of a pantoprazole(1-).
Classification
Small molecule
Drug classantiulcer agents (benzimidazole derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC
Identifiers
PDB—
CAS-ID102625-70-7
RxCUI—
ChEMBL IDCHEMBL1502
ChEBI ID7915
PubChem CID4679
DrugBankDB00213
UNII IDD8TST4O562 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Pantoprazole – Takeda
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Protonix – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Pantoloc control – Takeda
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Pantoprazole
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 13,800 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
91,777 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use